AIM ImmunoTech Inc (NYSE American:AIM)

1.83
Delayed Data
As of 12:57pm ET
 +0.05 / +2.81%
Today’s Change
0.39
Today|||52-Week Range
7.11
+236.40%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$78.9M

Company Description

AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.

Contact Information

AIM ImmunoTech, Inc.
2117 SW Highway 484
Ocala Florida 34473
P:(352) 448-7797
Investor Relations:

Employees

Shareholders

Other institutional5.10%
Mutual fund holders2.07%
Individual stakeholders1.07%

Top Executives

Thomas Kenwood EquelsExecutive Vice Chairman, President & CEO
Peter W. RodinoCOO, Secretary & General Counsel
Ellen M. LintalChief Financial Officer
David R. StrayerChief Scientific & Medical Officer